OPUS GENETICS INC. - COMMON STOCK

Ocuphire Appoints Jay Pepose, M.D., Ph.D., as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and Eyecelerator

19 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

06 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

29 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update

24 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy

16 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference

10 Mar 2022 09:27:42 By Nasdaq GlobeNewswire

Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

08 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations

08 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day

31 Jan 2022 06:00:00 By Nasdaq GlobeNewswire

Ocuphire to Host Virtual Investor R&D Day on January 31st

25 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January

05 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330

08 Dec 2021 08:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)

23 Nov 2021 09:00:01 By Nasdaq GlobeNewswire

Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update

12 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting

01 Nov 2021 09:30:31 By Nasdaq GlobeNewswire

Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases

07 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting

01 Oct 2021 08:49:48 By Nasdaq GlobeNewswire

Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall

27 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 Sep 2021 17:00:00 By Nasdaq GlobeNewswire

Ocuphire Pharma Presenting at Four Conferences in September

02 Sep 2021 07:00:02 By Nasdaq GlobeNewswire